Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Completed · Phase 1

Conditions studied: End-Stage Renal Disease, Hemodialysis

In brief

There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.

Key facts

Study ID

NCT01710020

Run by

Pfizer

People needed

12

Starts

2003-02-01

Expected to finish

2003-06-01

Last updated by the study team

2012-12-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with end-stage renal disease
• Subjects need hemodialysis 3 times weekly

You may not qualify if…

• Subjects with evidence or history of clinically significant disease, excluding those common for subjects with End-Stage Renal Disease (ESRD).
• Subjects with any condition possibly affecting drug absorption.
• Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin.

Where it is running

• Pfizer Investigational Site — Orlando, Florida, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.